Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 151 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline - Day 21 Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

NCT05294588
View directory record Official record
Conditions
Gonorrhea Male
Interventions
Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine
Drug · Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

NCT02790632
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
EG-1962 (nimodipine microparticles), Enteral Nimodipine
Drug
Lead sponsor
Edge Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma

NCT00504257
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Malignant Tumor of Peritoneum
Interventions
Avastin, Docetaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
4
States / cities
Fort Lauderdale, Florida • St. Petersburg, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 4, 2026, 6:40 PM EDT
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Terminated Phase 1 Interventional

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

NCT00278434
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Zoledronate, Placebo (Saline)
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield Study of Safety and Immunogenicity

NCT03352466
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NasoShield, BioThrax, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Melbourne, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With AS03

NCT01317758
View directory record Official record
Conditions
Influenza
Interventions
AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia

NCT03342404
View directory record Official record
Conditions
Thalassemia
Interventions
Luspatercept, Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

NCT05468736
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
6 Months to 11 Years
Enrollment
3,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
47
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Not yet recruiting Phase 1 Interventional

Magnetic Sentinel Lymph Node Mapping in Gastric Cancer

NCT05038098
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Gastrectomy, Indocyanine Green, Iron Conjugated Polymers in Saline Suspension
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines

NCT02415842
View directory record Official record
Conditions
Immunologic Tests
Interventions
Serum samples
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 64 Years
Enrollment
414 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pandemic Influenza Plasmid DNA Vaccines (Needle)

NCT00709800
View directory record Official record
Conditions
Influenza
Interventions
VCL-IPT1, VCL-IPM1, PBS
Biological
Lead sponsor
Vical
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
3
States / cities
San Diego, California • Baltimore, Maryland • Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 12, 2009 · Synced Oct 4, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NCT04163900
View directory record Official record
Conditions
Biliary Tract Cancer
Interventions
NUC-1031, Gemcitabine, Cisplatin
Drug
Lead sponsor
NuCana plc
Other
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Whittier, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 4, 2026, 6:40 PM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas

NCT00768339
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell
Interventions
AEG35156 antisense IV infusion
Drug
Lead sponsor
Aegera Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Burbank, California • Valhalla, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT01258608
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Mapatumumab, Placebo, Sorafenib
Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
9
States / cities
Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 4, 2026, 6:40 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

NCT03725059
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy, Radiation therapy, Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
45
States / cities
Daphne, Alabama • Goodyear, Arizona • Tucson, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

NCT02604433
View directory record Official record
Conditions
Erythrocyte Transfusion, Beta-Thalassemia
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 1 Interventional

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

NCT01340547
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
palifosfamide-tris, Normal Saline
Drug
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Dallas, Texas • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Withdrawn Phase 1 Interventional

Autologous Cell Therapy After Stroke

NCT00908856
View directory record Official record
Conditions
Stroke
Interventions
autologous bone marrow mononuclear cell transfusion, marrow stromal cells, placebo
Biological · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

NCT03635567
View directory record Official record
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab, Placebo to pembrolizumab
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
20
States / cities
Anchorage, Alaska • Phoenix, Arizona • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

NCT02374814
View directory record Official record
Conditions
Rabies
Interventions
Rabies vaccine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Oct 4, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas

NCT02868892
View directory record Official record
Conditions
Adenocarcinoma of the Cervix, Adenosquamous Cell Carcinoma of the Cervix
Interventions
Pemetrexed
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 4, 2026, 6:40 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dermal Tolerability of Dapsone Gel in Healthy Volunteers

NCT02117752
View directory record Official record
Conditions
Healthy Volunteers
Interventions
dapsone gel, dapsone gel vehicle, sodium lauryl sulfate, Normal saline
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
237 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 4, 2026, 6:40 PM EDT